298 related articles for article (PubMed ID: 30958071)
1. Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application.
Yang F; Zhao LN; Sun Y; Chen Z
J Int Med Res; 2019 May; 47(5):1817-1828. PubMed ID: 30958071
[TBL] [Abstract][Full Text] [Related]
2. Meta-Analysis of the Efficacy of Levosimendan in the Treatment of Severe Sepsis Complicated with Septic Cardiomyopathy.
Guan Q; Zhang C; Li B; Huang D; Li A; Qin J; Zhang X
Heart Surg Forum; 2023 Oct; 26(5):E609-E620. PubMed ID: 37920078
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy.
Sumanaru D; Josseran L; Essid A; Mbieleu B; Haegy I; Bergounioux J
Pediatr Cardiol; 2019 Mar; 40(3):668-670. PubMed ID: 30796500
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective and functional effects of levosimendan and milrinone in mice with cecal ligation and puncture-induced sepsis.
Yamashita S; Suzuki T; Iguchi K; Sakamoto T; Tomita K; Yokoo H; Sakai M; Misawa H; Hattori K; Nagata T; Watanabe Y; Matsuda N; Yoshimura N; Hattori Y
Naunyn Schmiedebergs Arch Pharmacol; 2018 Sep; 391(9):1021-1032. PubMed ID: 29922941
[TBL] [Abstract][Full Text] [Related]
5. The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts.
Behrends M; Peters J
Intensive Care Med; 2003 Oct; 29(10):1802-7. PubMed ID: 12879240
[TBL] [Abstract][Full Text] [Related]
6. Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials.
Chang W; Xie JF; Xu JY; Yang Y
BMJ Open; 2018 Mar; 8(3):e019338. PubMed ID: 29602841
[TBL] [Abstract][Full Text] [Related]
7. Effective use of levosimendan in anthracycline-induced cardiomyopathy: A case report.
Miaris N; Zezas S; Sgouros J; Zirou DC; Gkoura S; Stamoulis G; Angelopoulou H; Avgeropoulos G; Samantas E
Heart Lung; 2017; 46(5):382-386. PubMed ID: 28733066
[TBL] [Abstract][Full Text] [Related]
8. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
Prijić S; Rakić S; Nikolić L; Jovicić B; Stajević M; Vukomanović V; Kosutić J
Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
[TBL] [Abstract][Full Text] [Related]
9. Levosimendan reduces myocardial damage and improves cardiodynamics in streptozotocin induced diabetic cardiomyopathy via SERCA2a/NCX1 pathway.
Akhtar MS; Pillai KK; Hassan MQ; Dhyani N; Ismail MV; Najmi AK
Life Sci; 2016 May; 153():55-65. PubMed ID: 27058979
[TBL] [Abstract][Full Text] [Related]
10. Multiorgan Drug Action of Levosimendan in Critical Illnesses.
Pan J; Yang YM; Zhu JY; Lu YQ
Biomed Res Int; 2019; 2019():9731467. PubMed ID: 31641670
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis.
Liu DH; Ning YL; Lei YY; Chen J; Liu YY; Lin XF; Yang ZQ; Xian SX; Chen WT
Sci Rep; 2021 Oct; 11(1):20333. PubMed ID: 34645892
[TBL] [Abstract][Full Text] [Related]
12. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
[TBL] [Abstract][Full Text] [Related]
13. Inoprotection: the perioperative role of levosimendan.
Soeding PE; Royse CF; Wright CE; Royse AG; Angus JA
Anaesth Intensive Care; 2007 Dec; 35(6):845-62. PubMed ID: 18084975
[TBL] [Abstract][Full Text] [Related]
14. Effects of levosimendan in heart failure: The role of echocardiography.
Cameli M; Incampo E; Navarri R; Mandoli GE; Sciaccaluga C; Righini FM; Palmerini E; Sisti N; Mondillo S; Lunghetti S
Echocardiography; 2019 Aug; 36(8):1566-1572. PubMed ID: 31287582
[TBL] [Abstract][Full Text] [Related]
15. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock.
Oldner A; Konrad D; Weitzberg E; Rudehill A; Rossi P; Wanecek M
Crit Care Med; 2001 Nov; 29(11):2185-93. PubMed ID: 11700420
[TBL] [Abstract][Full Text] [Related]
16. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Cavusoglu Y
Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications.
Altenberger J; Gustafsson F; Harjola VP; Karason K; Kindgen-Milles D; Kivikko M; Malfatto G; Papp Z; Parissis J; Pollesello P; Pölzl G; Tschöpe C
J Cardiovasc Pharmacol; 2018 Mar; 71(3):129-136. PubMed ID: 28817484
[TBL] [Abstract][Full Text] [Related]
18. Septic cardiomyopathy in rat LPS-induced endotoxemia: relative contribution of cellular diastolic Ca(2+) removal pathways, myofibrillar biomechanics properties and action of the cardiotonic drug levosimendan.
Wagner S; Schürmann S; Hein S; Schüttler J; Friedrich O
Basic Res Cardiol; 2015 Sep; 110(5):507. PubMed ID: 26243667
[TBL] [Abstract][Full Text] [Related]
19. Comparison of dobutamine and levosimendan for treatment of sepsis-induced cardiac dysfunction: A protocol for systematic review and meta-analysis.
Guo J; Zhang X; Zhu Y; Cheng Q
Medicine (Baltimore); 2022 Mar; 101(11):. PubMed ID: 35356941
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: a meta-analysis and trial sequential analysis of randomized trials.
Xing Z; Tang L; Chen P; Huang J; Peng X; Hu X
Sci Rep; 2018 May; 8(1):7775. PubMed ID: 29773835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
